OTCQB:OCEL - Post by User
Post by
indaknownewfieon Apr 29, 2021 9:29pm
![](https://assets.stockhouse.com/kentico-cms/0340-00/images/Sprite.svg#id_Post_Views_Icon)
212 Views
Post# 33099017
Reposted from stocktwits
Reposted from stocktwitsWhere am I wrong here? Short term = $1 - $1.50 Indian EUA for Covid = $3 - $5 US EUA for Covid = $8 - $12 US approval/COPD = $12 - $15 US approval-OA = $20 Indian EUA is just days/weeks away. FDA knows the heat will be coming as to why they’ve had this in their lap since May 2020 and haven’t approved it, prompting Approval or Congressional hearings. And remember the key factor regarding Zofin and Covid.... Aviptadil ‘may’ get an EUA sooner, but was only trialed for severe Covid. Zofin is moderate to severe. So, a patient with risk factors of reaching severe Covid will get Zofin, not Aviptadil. If at-risk patients get Zofin, few if any ever reach the severe stage of Covid. Long haulers have already been treated with Zofin and have shown dramatic results long after Covid was gone (most have seen the news clip on this) COPD is next, then Osteoarthritis. Zofin is NOT a one-hit wonder! Do your DD and see for yourself!